| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
92,610,000 |
| Market
Cap: |
1.97(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$15.07 - $31.94 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Rocket Pharmaceuticals is a clinical-stage, multi-platform biotechnology company focused on the development of gene therapies for rare and devastating pediatric diseases. Co. has three clinical-stage ex vivo lentiviral vector. These include programs for Fanconi Anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells, Leukocyte Adhesion Deficiency-I, a genetic disorder that causes the immune system to malfunction, and Pyruvate Kinase Deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
1,355,932 |
| Total Buy Value |
$0 |
$0 |
$0 |
$19,999,997 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
385,818 |
434,774 |
477,485 |
503,595 |
| Total Sell Value |
$10,507,258 |
$11,964,318 |
$12,853,114 |
$13,363,000 |
| Total People Sold |
7 |
7 |
7 |
8 |
| Total Sell Transactions |
10 |
17 |
25 |
33 |
| End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Patel Kinnari |
See Remarks |
• • – |
2023-05-17 |
4 |
S |
$21.38 |
$28,429 |
D/D |
(1,330) |
213,993 |
|
5% |
|
| Shah Gaurav |
CEO |
• • – |
2023-05-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,979 |
525,764 |
|
- |
|
| Militello John |
See Remarks |
• • – |
2023-05-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
725 |
6,361 |
|
- |
|
| Patel Kinnari |
See Remarks |
• • – |
2023-05-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,989 |
215,323 |
|
- |
|
| Militello John |
See Remarks |
• • – |
2023-04-21 |
4 |
S |
$18.65 |
$43,678 |
D/D |
(2,342) |
5,636 |
|
13% |
|
| Militello John |
See Remarks |
• • – |
2023-04-18 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,364 |
7,978 |
|
- |
|
| White Mark Andrew |
Chief Medical Officer |
• • – |
2023-04-04 |
4 |
A |
$0.00 |
$0 |
D/D |
76,662 |
76,662 |
|
- |
|
| Militello John |
See Remarks |
• • – |
2023-02-17 |
4/A |
S |
$19.06 |
$20,509 |
D/D |
(1,076) |
1,782 |
|
- |
|
| Militello John |
See Remarks |
• • – |
2023-02-17 |
4 |
S |
$19.06 |
$23,711 |
D/D |
(1,244) |
1,614 |
|
-3% |
|
| Shah Gaurav |
CEO |
• • – |
2023-02-17 |
4 |
S |
$19.06 |
$232,418 |
D/D |
(12,194) |
536,885 |
|
-3% |
|
| Schwartz Jonathan David |
See Remarks |
• • – |
2023-02-17 |
4 |
S |
$19.06 |
$67,796 |
D/D |
(3,557) |
94,546 |
|
-3% |
|
| Shah Gaurav |
CEO |
• • – |
2023-02-14 |
4 |
A |
$0.00 |
$0 |
D/D |
67,785 |
737,859 |
|
- |
|
| Patel Kinnari |
See Remarks |
• • – |
2023-02-14 |
4 |
A |
$0.00 |
$0 |
D/D |
38,735 |
405,018 |
|
- |
|
| Wilson Martin |
General Counsel |
• • – |
2023-02-14 |
4 |
A |
$0.00 |
$0 |
D/D |
16,947 |
66,810 |
|
- |
|
| Militello John |
See Remarks |
• • – |
2023-02-14 |
4 |
A |
$0.00 |
$0 |
D/D |
11,067 |
57,729 |
|
- |
|
| Militello John |
See Remarks |
• • – |
2023-02-14 |
4/A |
OE |
$0.00 |
$0 |
D/D |
2,858 |
2,858 |
|
- |
|
| Schwartz Jonathan David |
See Remarks |
• • – |
2023-02-14 |
4/A |
OE |
$0.00 |
$0 |
D/D |
8,574 |
98,103 |
|
- |
|
| Shah Gaurav |
CEO |
• • – |
2023-02-14 |
4/A |
OE |
$0.00 |
$0 |
D/D |
31,440 |
549,079 |
|
- |
|
| Patel Kinnari |
See Remarks |
• • – |
2023-02-14 |
4/A |
OE |
$0.00 |
$0 |
D/D |
15,720 |
166,566 |
|
- |
|
| Wong Roderick |
Director |
– • • |
2022-12-01 |
4 |
A |
$0.00 |
$0 |
I/I |
529,038 |
18,157,605 |
|
- |
|
| Wong Roderick |
Director |
– • • |
2022-10-06 |
4 |
B |
$14.75 |
$19,999,997 |
I/I |
1,355,932 |
17,628,567 |
2.25 |
8% |
|
| Patel Kinnari |
See Remarks |
• • – |
2022-08-12 |
4 |
A |
$0.00 |
$0 |
D/D |
52,489 |
366,283 |
|
- |
|
| Wilson Martin |
General Counsel |
• • – |
2022-08-12 |
4 |
A |
$0.00 |
$0 |
D/D |
28,763 |
49,863 |
|
- |
|
| Militello John |
See Remarks |
• • – |
2022-08-12 |
4 |
A |
$0.00 |
$0 |
D/D |
14,310 |
46,662 |
|
- |
|
| Militello John |
See Remarks |
• • – |
2022-04-18 |
4 |
A |
$0.00 |
$0 |
D/D |
7,932 |
32,352 |
|
- |
|
142 Records found
|
|
Page 3 of 6 |
|
|
0.13 (0.61%) 
